J&J-Linked Rapport Therapeutics Files For IPO
By Ben Glickman
Johnson & Johnson-linked biopharmaceutical company Rapport Therapeutics on Friday filed for an initial public offering with the Securities and Exchange Commission.
The Boston-based company is looking to develop small-molecule medicines to treat central nervous system disorders. The company is evaluating potential candidates to treat epilepsy, peripheral neuropathic pain and bipolar disorder.
Rapport did not say how many shares it planned sell or give an anticipated price range for the offering. The company has applied to list its shares on the Nasdaq Global Market under the ticker RAPP.
The company was founded in 2022 with the support of Johnson & Johnson Innovation and Third Rock Ventures. Chief Scientific Officer David Bredt previously led neuroscience discovery at Janssen Pharmaceutica, and Rapport has a licensing agreement with Janssen for developing and commercializing certain products created by Bredt and colleagues at Janssen.
Rapport lists Johnson & Johnson Innovation, Cormorant, Fidelity and Third Rock Ventures among its major stockholders.
Goldman Sachs, Jefferies, TD Securities and Stifel Nicolaus are acting as underwriters of the offering.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
May 17, 2024 16:38 ET (20:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Friday’s Job Report in Focus
-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now